Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 22037-1-AP - Provider product page
- Provider
- Proteintech Group
- Product name
- Bim antibody
- Antibody type
- Polyclonal
- Description
- Bim antibody (Cat. #22037-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse and has been validated for the following applications: IHC, WB, ELISA.
- Reactivity
- Human, Mouse
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references One-Two Punch Therapy for the Treatment of T-Cell Malignancies Involving p53-Dependent Cellular Senescence.
HES5-mediated repression of LIGHT transcription may contribute to apoptosis in hepatocytes.
Inhibition of Bcl-2 and Bcl-xL overcomes the resistance to the third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer.
Inhibition of FOXO1 by small interfering RNA enhances proliferation and inhibits apoptosis of papillary thyroid carcinoma cells via Akt/FOXO1/Bim pathway.
Qing Y, Li H, Zhao Y, Hu P, Wang X, Yu X, Zhu M, Wang H, Wang Z, Guo Q, Hui H
Oxidative medicine and cellular longevity 2021;2021:5529518
Oxidative medicine and cellular longevity 2021;2021:5529518
HES5-mediated repression of LIGHT transcription may contribute to apoptosis in hepatocytes.
Miao X, Guo Y, Zeng S, Liu X, Teng X, Li L, Hong W
Cell death discovery 2021 Oct 23;7(1):308
Cell death discovery 2021 Oct 23;7(1):308
Inhibition of Bcl-2 and Bcl-xL overcomes the resistance to the third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer.
Lu Y, Bian D, Zhang X, Zhang H, Zhu Z
Molecular medicine reports 2021 Jan;23(1)
Molecular medicine reports 2021 Jan;23(1)
Inhibition of FOXO1 by small interfering RNA enhances proliferation and inhibits apoptosis of papillary thyroid carcinoma cells via Akt/FOXO1/Bim pathway.
Song HM, Song JL, Li DF, Hua KY, Zhao BK, Fang L
OncoTargets and therapy 2015;8:3565-73
OncoTargets and therapy 2015;8:3565-73
No comments: Submit comment
No validations: Submit validation data